IRONWOOD PHARMACEUTICALS, INC. Gain (Loss) on Sale of Derivatives
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Gain (Loss) on Sale of Derivatives of $3.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfDerivatives · last filed 2020-02-13
- IRONWOOD PHARMACEUTICALS, INC. gain (loss) on sale of derivatives for the quarter ending 2019-09-30 was $4.80M.
- IRONWOOD PHARMACEUTICALS, INC. gain (loss) on sale of derivatives for the quarter ending 2015-12-31 was $1.60M, a 84.31% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. gain (loss) on sale of derivatives for the quarter ending 2015-09-30 was $11.40M.
- IRONWOOD PHARMACEUTICALS, INC. gain (loss) on sale of derivatives for the quarter ending 2015-06-30 was $200.00K.
- IRONWOOD PHARMACEUTICALS, INC. gain (loss) on sale of derivatives for fiscal 2019 was $3.00M.
| Period end | Gain (Loss) on Sale of Derivatives 3 month | Gain (Loss) on Sale of Derivatives 6 month | Gain (Loss) on Sale of Derivatives 9 month | Gain (Loss) on Sale of Derivatives 12 month |
|---|---|---|---|---|
| 2019-12-31 | $3.00M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $4.80M 10-Q · filed 2019-10-31 | |||
| 2015-12-31 | $1.60M 10-K · filed 2016-02-19 | $13.00M derived: sum of 2 quarters · filed 2016-02-19 | $13.20M derived: sum of 3 quarters · filed 2016-02-19 | |
| 2015-09-30 | $11.40M 10-K · filed 2016-02-19 | $11.60M derived: sum of 2 quarters · filed 2016-02-19 | ||
| 2015-06-30 | $200.00K 10-K · filed 2016-02-19 | |||
| 2014-12-31 | $10.20M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |